Evidence map›Paper›PMID 42781103›Full record

ArticleMaterials today. Bio2026

Microbiota-derived self-adjuvanting exopolysaccharide-based codelivery system for potent cancer immunotherapy.

Xuemei Bao, Jiamin Shi, Haochi Zhang, Chunhe Li, Yanchen Liang, Na Pan, Yubing Fu, Xing Su, Wan Wang, Ting Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xuemei BaoSchool of Life Sciences, Inner Mongolia University, Hohhot, 010021, China.
Jiamin ShiSchool of Life Sciences, Inner Mongolia University, Hohhot, 010021, China.
Haochi ZhangSchool of Life Sciences, Inner Mongolia University, Hohhot, 010021, China.
Chunhe LiSchool of Life Sciences, Inner Mongolia University, Hohhot, 010021, China.
Yanchen LiangSchool of Life Sciences, Inner Mongolia University, Hohhot, 010021, China.
Na PanSchool of Life Sciences, Inner Mongolia University, Hohhot, 010021, China.
Yubing FuSchool of Life Sciences, Inner Mongolia University, Hohhot, 010021, China.
Xing SuSchool of Life Sciences, Inner Mongolia University, Hohhot, 010021, China.
Wan WangSchool of Life Sciences, Inner Mongolia University, Hohhot, 010021, China.
Ting WangSchool of Life Sciences, Inner Mongolia University, Hohhot, 010021, China.
Lipeng ZhangAffiliated Hospital of Inner Mongolia Medical University, Hohhot, 010030, China.
Xiao WangSchool of Life Sciences, Inner Mongolia University, Hohhot, 010021, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer vaccines hold great promise by eliciting antigen-specific T cell responses against tumors; however, their efficacy remains limited by poor coordination between antigen delivery and innate immune activation. Here, microbiota-derived metabolites (exopolysaccharides, EPSs) are presented as a self-adjuvanting codelivery system that simultaneously delivers the Toll-like receptor 7/8 (TLR7/8) agonist R848 and ovalbumin (OVA). This bi-adjuvant nanovaccine (EPS@R848/OVA) rapidly accumulates in draining lymph nodes (dLNs) as early as 6 h after administration and significantly enhances the uptake and activation of CD103

Indexed as

Cancer immunotherapyCD8+ T cell responsesCodeliveryConventional dendritic cellsExopolysaccharidesSelf-assembly

Identifiers

PMID42781103
PMCPMC13598176

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.